Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAD Study of Zifanocycline in Healthy Subjects
NCT04532957Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zifanocycline in community-acquired bacterial pneumonia (CAP), acute bacterial skin and skin structure infections (ABSSSI) and Intra-abdominal infection (IAI) (3 arms), sponsored by KBP Biosciences. Primary endpoint: Safety and Tolerability. Started Aug 2020; status: completed.
02
Drugs
zifanocycline
03
Conditions
community-acquired bacterial pneumonia (CAP)acute bacterial skin and skin structure infections (ABSSSI)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT04532957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532957.